 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- | ADS024 / Adiso Therap
Journal: LPA3 agonist-producing Bacillus velezensis ADS024 is efficacious in multiple neuroinflammatory disease models. (Pubmed Central) - Sep 7, 2024
ADS024 efficacy was partially inhibited by Ki16425 in vivo suggesting LPA3 may be part of its mechanism. Altogether, these data suggest that ADS024 and its LPA3 agonism activity should be investigated further as a possible treatment for diseases with a neuroinflammatory component.
- | ADS024 / Adiso Therap
Preclinical, Journal, IO biomarker: ADS024, a single-strain live biotherapeutic product of Bacillus velezensis alleviates dextran sulfate-mediated colitis in mice, protects human colonic epithelial cells against apoptosis, and maintains epithelial barrier function. (Pubmed Central) - Jan 25, 2024
in dextran sodium sulfate (DSS)-treated mice with colitis. Thus, ADS024 may protect the colonic epithelial barrier in UC via anti-inflammatory, anti-apoptotic, and tight-junction protection mechanisms.
- | ADS024 / Adiso Therap
Preclinical, Journal: Novel, non-colonizing, single-strain live biotherapeutic product ADS024 protects against Clostridioides difficile infection challenge in vivo. (Pubmed Central) - Sep 20, 2023
Thus, ADS024 may protect the colonic epithelial barrier in UC via anti-inflammatory, anti-apoptotic, and tight-junction protection mechanisms. Our findings, demonstrating in vivo efficacy of ADS024 in protecting against CDI challenge in mouse models, support the use of ADS024 in preventing recurrent CDI following standard antibiotic treatment.
- | ADS051 / Adiso Therap
Journal: Development of ADS051, an oral, gut-restricted, small molecule neutrophil modulator for the treatment of neutrophil-mediated inflammatory diseases. (Pubmed Central) - Aug 3, 2023
In addition, preclinical toxicology studies in rats and monkeys receiving daily oral doses of ADS051 for 28?days did not reveal safety risks or ADS051-related toxicity. Our results to date support the clinical development of ADS051 in patients with neutrophil-mediated inflammatory diseases.
- ADS024 / Adiso Therap
ADS024, a Bacillus velezensis Strain, for Prevention of Recurrence of Clostridioides difficile Infection: Results From a Randomized, Placebo-Controlled, Double-Blind, Phase 1b Study (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_646;
P1
Adverse event data show ADS024 was well-tolerated (Table). Recurrence was observed in 4/27 patients (15%, 3/4 rCDI) treated with ADS024 (median TTR, 10 days [range, 2-14]) and 1 (11%) with placebo (TTR, 108 days).
- ADS051 / Adiso Therap
ADS051, an Oral, Gut-Restricted, Small Molecule Neutrophil Modulator in Patients With Moderate-To-Severe Ulcerative Colitis: Results From a Multiple Ascending Dose Study (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_645;
P1
No serious adverse events were reported. No TEAE resulted in dose modification or drug discontinuation.
- ADS024 / Adiso Therap
ADS024, a single strain live biotherapeutic product, attenuates MOG-EAE induced clinical symptoms in mice and zebrafish (Gold) - Jul 21, 2023 - Abstract #MSMilan2023MSMilan_1086;
Mice were treated orally D0-23 with saline (BID; n=4), ADS024 (5x108 colony forming units (CFU) BID; n=12), positive control FTY720 (3 mg/kg QD; n=8)...Larvae (6 dpf) were treated by addition of ADS024 (4x106 CFU/ml), or positive control Tecfidera (2 ug/g); n=24/group... Oral treatment of MOG-EAE murine and zebrafish models with SS-LBP ADS024 improved clinical symptoms and motor movement suggesting potential for treatment of MS.
- | ADS032 / Adiso Therap
Journal: A novel dual NLRP1 and NLRP3 inflammasome inhibitor for the treatment of inflammatory diseases. (Pubmed Central) - Jun 26, 2023
Critically, ADS032 protected mice from lethal influenza A virus challenge, displayed increased survival and reduced pulmonary inflammation. ADS032 is the first described dual inflammasome inhibitor and a potential therapeutic to treat both NLRP1- and NLRP3-associated inflammatory diseases and also constitutes a novel tool that allows examination of the role of NLRP1 in human disease.
- ADS024 / Adiso Therap
ADS024, A SINGLE STRAIN LIVE BIOTHERAPEUTIC PRODUCT OF BACILLUS VELEZENSIS, PROTECTS HUMAN COLONIC EPITHELIAL CELLS AGAINST APOPTOSIS AND MAINTAINS EPITHELIAL BARRIER FUNCTION (South Hall A, Poster Hall - McCormick Place) - Mar 23, 2023 - Abstract #DDW2023DDW_4502;
Conclusion : ADS024 filtrate exhibits direct anti-inflammatory and anti-apoptotic effects on intestinal explants from IBD patients. ADS024 filtrate specifically prevents caspase 3-dependent apoptosis and maintains the barrier functions of human intestinal epithelial cells.
- ADS024 / Adiso Therap
ADS024 in patients recently cured of a Clostridioides difficile infection: results from a randomised, placebo-controlled, double-blind, phase 1b study (Hall L) - Mar 13, 2023 - Abstract #ECCMID2023ECCMID_5407;
- | ADS024 / Adiso Therap
Journal: ADS024, a Bacillus velezensis strain, protects human colonic epithelial cells against C. difficile toxin-mediated apoptosis. (Pubmed Central) - Jan 28, 2023
The anti-apoptotic effects of ADS024 filtrate and ethyl acetate extract were dependent on the inhibition of caspase 3 cleavage. The sterile filtrate, but not ethyl acetate extract, of ADS024 partially degraded toxin B. ADS024 inhibits toxin B-mediated apoptosis in human colonic epithelial cells and colonic explants.
- || ADS051 / Adiso Therap
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: SCOUT: An Investigation of Oral BT051 in Subjects With Moderately to Severely Active Ulcerative Colitis (UC) (clinicaltrials.gov) - Dec 15, 2022
P1, N=24, Completed, Sponsor: Adiso Therapeutics
The sterile filtrate, but not ethyl acetate extract, of ADS024 partially degraded toxin B. ADS024 inhibits toxin B-mediated apoptosis in human colonic epithelial cells and colonic explants. Recruiting --> Completed | N=44 --> 24 | Trial completion date: Aug 2023 --> Nov 2022 | Trial primary completion date: Aug 2023 --> Nov 2022
- || ADS024 / Adiso Therap
Trial completion, Trial completion date, Trial primary completion date: A Study of ART24 in Subjects Recently Cured of a Clostridioides Difficile Infection (CDI) (clinicaltrials.gov) - Oct 17, 2022
P1, N=36, Completed, Sponsor: Adiso Therapeutics
Recruiting --> Completed | N=44 --> 24 | Trial completion date: Aug 2023 --> Nov 2022 | Trial primary completion date: Aug 2023 --> Nov 2022 Active, not recruiting --> Completed | Trial completion date: Feb 2023 --> Oct 2022 | Trial primary completion date: Nov 2022 --> Jul 2022
- ADS024 / Adiso Therap
ADS024, a Single Strain Live Biotherapeutic Product, Reduces Colonic Inflammation in DSS-Induced Colitis When Dosed Twice Daily (Crown Ballroom) - Sep 4, 2022 - Abstract #ACG2022ACG_3358;
This ADS024 dosing regimen also decreased mean colon weight:length ratio, a measure of inflammation, as compared to controls (p< 0.005 respectively). The anti-p40 mAb, with a mechanism of action similar to ustekinumab, an approved treatment for UC, reduced DAI but did not significantly reduce colon weight:length ratio.
- | ADS024 / Adiso Therap
Journal: Identification of ADS024, a newly characterized strain of Bacillus velezensis with direct Clostridiodes difficile killing and toxin degradation bio-activities. (Pubmed Central) - Jun 8, 2022
In addition to directly killing C. difficile, ADS024 also produces proteases capable of degrading C. difficile toxins, the drivers of symptoms associated with most cases of CDI. ADS024 is in clinical development for the prevention of CDI recurrence as a single-strain live biotherapeutic product, and this initial data set supports further studies aimed at evaluating ADS024 in future human clinical trials.
- ADS024 / Adiso Therap, ADS051 / Adiso Therap
Adiso Therapeutics (Theater 1) - Jun 4, 2022 - Abstract #BIO2022BIO_21;
Adiso has built these programs upon a rich history of institutional and academic collaboration, including the University College Cork, Ireland, the APC Microbiome Institute, the University of Massachusetts Chan Medical School, the Hudson Institute of Medical Sciences Centre for Innate Immunity and Infectious Diseases in Australia and the University of Edinburgh Centre for Inflammation Research. Adiso was founded in 2022 and is based in Concord, MA,
- ADS024 / Adiso Therap
ART24, A BACILLUS VELEZENSIS STRAIN, PROTECTS HUMAN COLONIC EPITHELIAL CELLS AGAINST CLOSTRIDIOIDES DIFFICILE TOXIN-MEDIATED APOPTOSIS (20AB - San Diego Convention Center) - Apr 25, 2022 - Abstract #DDW2022DDW_5434;
Both ART24 filtrate and ART24 culture media extract inhibited cleaved caspase 3 protein expression in toxin B-treated fresh human colonic tissues. Conclusion : ART24 produces proteases and metabolites with anti-apoptotic properties that are protective against toxin B in human colonic epithelial cells.
- || ADS024 / Adiso Therap
Enrollment closed: A Study of ART24 in Subjects Recently Cured of a Clostridioides Difficile Infection (CDI) (clinicaltrials.gov) - Mar 27, 2022
P1, N=36, Active, not recruiting, Sponsor: Adiso Therapeutics
Conclusion : ART24 produces proteases and metabolites with anti-apoptotic properties that are protective against toxin B in human colonic epithelial cells. Recruiting --> Active, not recruiting
- | ADS051 / Adiso Therap
Trial primary completion date: SCOUT: An Investigation of Oral BT051 in Subjects With Moderately to Severely Active Ulcerative Colitis (UC) (clinicaltrials.gov) - Jan 17, 2022
P1, N=44, Recruiting, Sponsor: Bacainn Therapeutics, Inc.
Recruiting --> Active, not recruiting Trial primary completion date: May 2023 --> Aug 2023
- || ADS051 / Adiso Therap
New P1 trial: A Phase 1, Single-Ascending-Dose Study of BT051 in Healthy Subjects (clinicaltrials.gov) - Nov 2, 2021
P1, N=50, Completed, Sponsor: Bacainn Therapeutics, Inc.
- | ADS051 / Adiso Therap
New P1 trial: SCOUT: An Investigation of Oral BT051 in Subjects With Moderately to Severely Active Ulcerative Colitis (UC) (clinicaltrials.gov) - Oct 18, 2021
P1, N=44, Recruiting, Sponsor: Bacainn Therapeutics, Inc.
- || ADS024 / Adiso Therap
Enrollment change, Trial completion date, Trial primary completion date: A Study of ART24 in Subjects Recently Cured of a Clostridioides Difficile Infection (CDI) (clinicaltrials.gov) - Sep 28, 2021
P1, N=36, Recruiting, Sponsor: Artugen Therapeutics USA, Inc.
Trial primary completion date: May 2023 --> Aug 2023 N=16 --> 36 | Trial completion date: Mar 2022 --> Feb 2023 | Trial primary completion date: Jan 2022 --> Nov 2022
- BT051 / Bacainn Therap
[VIRTUAL] Safety, tolerability and pharmacokinetics of BT051, an oral inhibitor of neutrophil migration and activation in clinical development for Inflammatory Bowel Disease (Virtual Poster Exhibition) - Jun 3, 2021 - Abstract #ECCOIBD2021ECCO_IBD_1322;
Conclusion Single ascending doses up to 3500 mg of BT051 were safe and well-tolerated in healthy subjects. Stool concentrations out to 7 days postdose that exceed the expected efficacious threshold, minimal to no systemic exposure and the lack of systemic immunosuppression support the continued development of BT051 as a gut-targeted therapy for patients with IBD.
- | ADS024 / Adiso Therap
New P1 trial: A Study of ART24 in Subjects Recently Cured of a Clostridioides Difficile Infection (CDI) (clinicaltrials.gov) - May 19, 2021
P1, N=16, Recruiting, Sponsor: Artugen Therapeutics USA, Inc.